IDH1 and acute myeloid leukemia: Secondary resistance to ivosidenib is also characterized by the onset of 2-HG restoring mutations, such as second-site mutations in the IDH1 gene and canonical mutations of IDH2, which can co-occur in ivosidenib-resistant AML [121].